New ADME/Tox Products Enable More In Vivo-like Testing
Complete the form below to unlock access to ALL audio articles.
Corning Incorporated has expanded its ADME/Tox product offerings to include Corning® TransportoCells™ HEK293-derived ABC transporter membrane vesicles and Corning Supersomes™ Ultra Human Aldehyde Oxidase (AO) enzyme.
Building on its large line of Corning Gentest™ in vitro transporter models, TransportoCells provide an innovative cell model for solute carrier (SLC) transporter studies. Corning has now developed ATP-binding cassette (ABC) transporter membrane vesicles based on the TransportoCells technology platform using a mammalian cell expression system.
“Inside-out membrane vesicles have been considered a gold standard for studying drug-drug interactions with ABC transporters,” said Dr. Tony Frutos, business technology director for Corning Life Sciences. “But the membrane vesicles made from insect Sf9 cells infected with baculovirus have different membrane components from mammalian cells – as well as different protein post-translation modifications – and they sometimes lack consistency.”
Corning’s new ABC transporter vesicles are made from HEK cells transiently transfected to over-express a single human ABC transporter protein. Using this mammalian expression system, the new products avoid many disadvantages associated with insect cell expression systems. The product portfolio now includes four human ABC transporter vesicles and a control vesicle.
The company is also extending its line of Corning Gentest Supersome recombinant metabolic enzymes using a mammalian expression system. Corning Supersome Ultra Human AO is a stable and reliable in vitro tool for the study of AO-mediated metabolism, which has increasing importance in drug development. As a robust and consistent screening platform, Corning Supersomes Ultra Human AO delivers significantly higher (3- to 4-fold higher) activity as compared to bacterial expression systems.
